Validation of the French national health insurance information system as a tool in vaccine safety assessment: Application to febrile convulsions after pediatric measles/mumps/rubella immunization

Vaccine

Volumn 31, Issue 49, 2013, Pages 5856-5862

  Hanf, Matthieu ^a   Quantin, Catherine ^b,c   Farrington, Paddy ^d   Benzenine, Eric ^b   Hocine, N Mounia ^e   Velten, Michel ^f,g   Tubert Bitter, Pascale ^a   Escolano, Sylvie ^a  

^a CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^b DIJON UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

^d OPEN UNIVERSITY   (United Kingdom)

^e Unité de Recherches Mesures Physiques Métrologie   (France)

^f UNIVERSITÉ DE STRASBOURG   (France)

^g Paul Strauss Comprehensive Cancer Center   (France)

Author keywords

Febrile convulsions; French national health insurance regime information system; Measles mumps rubella vaccine; Pharmacoepidemiology; Self controlled case series; Vaccine safety

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; PNEUMOCOCCUS VACCINE;

ARTICLE; DRUG SAFETY; FEBRILE CONVULSION; HOSPITALIZATION; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MEASLES; MEDICAL INFORMATION SYSTEM; MUMPS; NATIONAL HEALTH INSURANCE; PRIORITY JOURNAL; REIMBURSEMENT; RUBELLA;

FC; FEBRILE CONVULSION; FEBRILE CONVULSIONS; FRENCH NATIONAL HEALTH INSURANCE INFORMATION SYSTEM; FRENCH NATIONAL HEALTH INSURANCE REGIME INFORMATION SYSTEM; GENERAL PRACTITIONER; GP; ICD-10; INCIDENCE RATE RATIO; INTERNATIONAL STATISTICAL CLASSIFICATION OF DISEASES, TENTH REVISION; IRR; MEASLES/MUMPS/RUBELLA; MEASLES/MUMPS/RUBELLA VACCINE; MMR; PCV; PHARMACOEPIDEMIOLOGY; PNEUMOCOCCAL CONJUGATE VACCINE; SCCS; SELF CONTROLLED CASE SERIES; SELF-CONTROLLED CASE SERIES; SNIIR-AM; VACCINE SAFETY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; CHILD, PRESCHOOL; FRANCE; HOSPITALIZATION; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MEASLES-MUMPS-RUBELLA VACCINE; NATIONAL HEALTH PROGRAMS; PRODUCT SURVEILLANCE, POSTMARKETING; RISK; SEIZURES, FEBRILE;

EID: 84887606673     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.09.052     Document Type: Article

References (20)

1. Ozawa S., Mirelman A., Stack M.L., Walker D.G., Levine O.S. Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review. Vaccine 2012, 31(1):96-108.
2. Maurice J.M., Davey S., World Health Organization, UNICEF, World Bank State of the world's vaccines and immunization 2009, World Health Organization, Geneva.
3. Duclos P. A global perspective on vaccine safety. Vaccine 2004, 22:2059-2063.
4. Begg N., Miller E. Role of epidemiology in vaccine policy. Vaccine 1990, 8:180-189.
5. Jacobson R.M., Adegbenro A., Pankratz V.S., Poland G.A. Adverse events and vaccination - the lack of power and predictability of infrequent events in pre-licensure study. Vaccine 2001, 19:2428-2433.
6. Rosenthal S., Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. American Journal of Public Health 1995, 85:1706-1709.
7. Chen R.T., Glasser J.W., Rhodes P.H., Davis R.L., Barlow W.E., Thompson R.S., et al. Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics 1997, 99:765-773.
8. Verstraeten T., DeStefano F., Chen R.T., Miller E. Vaccine safety surveillance using large linked databases: opportunities, hazards and proposed guidelines. Expert Review of Vaccines 2003, 2:21-29.
9. Farrington P., Pugh S., Colville A., Flower A., Nash J., Morgan-Capner P., et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995, 345:567-569.
10. Tuppin P., de Roquefeuil L., Weill A., Ricordeau P., Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Revue d Epidemiologie et de Sante Publique 2010, 58:286-290.
11. Martin-Latry K., Bégaud B. Pharmacoepidemiological research using French reimbursement databases: yes we can!. Pharmacoepidemiology and Drug Safety 2010, 19:256-265.
12. Jefferson T., Price D., Demicheli V., Bianco E. Unintended events following immunization with MMR: a systematic review. Vaccine 2003, 21:3954-3960.
13. Barlow W.E., Davis R.L., Glasser J.W., Rhodes P.H., Thompson R.S., Mullooly J.P., et al. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine. New England Journal of Medicine 2001, 345:656-661.
14. Vestergaard M., Hviid A., Madsen K.M., Wohlfahrt J., Thorsen P., Schendel D., et al. MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. Journal of the American Medical Association 2004, 292:351-357.
15. Miller E., Andrews N., Stowe J., Grant A., Waight P., Taylor B. Risks of convulsion and aseptic meningitis following measles-mumps-rubella vaccination in the United Kingdom. American Journal of Epidemiology 2007, 165:704-709.
16. Gold M., Dugdale S., Woodman R.J., McCaul K.A. Use of the Australian Childhood Immunisation Register for vaccine safety data linkage. Vaccine 2010, 28:4308-4311.
17. Haut Conseil de la santé publique 2012 vaccination schedule and recommendations from the "Haut Conseil de la santé publique" in France. Bulletin épidémiologique hebdomadaire 2012, 14-15:163-186.
18. Fonteneau L., Guthmann J.-P., Collet M., Vilain A., Herbet J.B., Lévy-Bruhl D. Vaccination coverage estimated based on data found in 24th month health certificates of infants France, 2004-2007. Bulletin épidémiologique hebdomadaire 2010, 31-32.
19. Blanc P. The vaccination policy in France 2007, Office parlementaire d'évaluation des politiques de santé, Paris.
20. Miller E., Goldacre M., Pugh S., Colville A., Farrington P., Flower A., et al. Risk of aseptic meningitis after measles, mumps, and rubella vaccine in UK children. Lancet 1993, 341:979-982.